Immunotherapy with antibodies to the EGF receptor.
A series of rat monoclonal antibodies (MAbs) has been generated against the extracellular domain of the receptor for EGF which block the binding of EGF and TGF alpha to the receptor and inhibit the growth in vitro of a range of carcinoma cell lines that over-express the receptor for EGF. Some of these antibodies were able also to induce the complete regression of xenografts of EGFR-over-expressing tumours when treatment was started, either at the time of tumour inoculation or later when the tumours were established. The most effective of these antibodies was ICR62, which was also able to activate host immune effector functions. We conclude that antibodies which block growth-factor-ligand interaction can have a profound influence on the proliferative capacity of tumour cells in vivo and may have useful clinical application.
Dean
C
C
Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, UK.
Modjtahedi
H
H
Eccles
S
S
Box
G
G
Styles
J
J
D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis / Q000627:therapeutic use* / Q000633:toxicity*; D001665:Binding Sites; D001943:Breast Neoplasms / Q000473:pathology / Q000628:therapy; D002277:Carcinoma / Q000473:pathology / Q000628:therapy*; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D004815:Epidermal Growth Factor / Q000378:metabolism; D066246:ErbB Receptors / Q000096:biosynthesis / Q000276:immunology* / Q000378:metabolism; D005260:Female; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects; D006258:Head and Neck Neoplasms / Q000473:pathology / Q000628:therapy; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008175:Lung Neoplasms / Q000473:pathology / Q000628:therapy; D051379:Mice; D008819:Mice, Nude; D010051:Ovarian Neoplasms / Q000473:pathology / Q000628:therapy; D051381:Rats; D011919:Rats, Inbred Strains / Q000276:immunology; D011994:Recombinant Proteins / Q000276:immunology; D016211:Transforming Growth Factor alpha / Q000276:immunology; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000628:therapy; D014846:Vulvar Neoplasms / Q000473:pathology / Q000628:therapy
D000911:Antibodies, Monoclonal; D011994:Recombinant Proteins; D016211:Transforming Growth Factor alpha; D004815:Epidermal Growth Factor; D066246:ErbB Receptors